Immune effector cells toxicity management

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
Page co-editor Page co-editor
Leyre Zubiri, MD, PhD
Massachusetts General Hospital
Boston, MA
Matthew Hadfield, DO
Lifespan/Brown University
Providence, RI
LinkedIn

The purpose of this page is to address the management of toxicity from bispecific T-cell engager and immune effector cell (IEC) therapy, notably CAR-T. There is a separate page for the management of immune checkpoint inhibitor (ICI) toxicities, available here.

  • We have moved How I Treat articles to a dedicated page.


Guidelines

Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.

ASCO

ASTCT

Consensus recommendations

EBMT/JACIE/EHA

SITC

REMS programs for CAR T-cells